Advertisement

Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!

  • Alexandre T.J. Maria
    Affiliations
    Internal Medicine & Immuno-Oncology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France
    Search for articles by this author
  • Clement Delmas
    Affiliations
    Cardiology Department INI-CRT PhyMedExp INSERM CNRS CHU de Montpellier Université de Montpellier France, France
    Search for articles by this author
  • Cyrille Coustal
    Affiliations
    Department of Internal Medicine, Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France
    Search for articles by this author
  • Pascale Palassin
    Affiliations
    Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France
    Search for articles by this author
  • François Roubille
    Correspondence
    Corresponding author: Intensive Cardiac Care Unit, Cardiology Department, Montpellier, France; PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214. 34295 Montpellier cedex 5, France.
    Affiliations
    Cardiology Department INI-CRT PhyMedExp INSERM CNRS CHU de Montpellier Université de Montpellier France, France
    Search for articles by this author
Published:October 28, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.028
      The Immune checkpoint blockers (ICB) have greatly improved clinical outcomes in multiple cancer types and are increasingly being used in earlier disease settings alone or in combination with other therapies. However, rare but life-threatening complications defined as immune-related adverse events (irAE) as ICI-induced myocarditis can occur, justifying close monitoring and specific management [
      • Moslehi J.J.
      • Salem J.E.
      • Sosman J.A.
      • Lebrun-Vignes B.
      • Johnson D.B.
      Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
      ,
      • Moslehi J.J.
      • Johnson D.B.
      • Sosman J.A.
      Myocarditis with immune checkpoint blockade.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Moslehi J.J.
        • Salem J.E.
        • Sosman J.A.
        • Lebrun-Vignes B.
        • Johnson D.B.
        Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
        Lancet. 2018; 391: 933
        • Moslehi J.J.
        • Johnson D.B.
        • Sosman J.A.
        Myocarditis with immune checkpoint blockade.
        N Engl J Med. 2017; 376: 292
        • Drobni Z.D.
        • Alvi R.M.
        • Taron J.
        • Zafar A.
        • Murphy S.P.
        • Rambarat P.K.
        • et al.
        Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.
        Circulation. 2020; 142: 2299-2311
        • Lyon A.R.
        • López-Fernández T.
        • Couch L.S.
        • Asteggiano R.
        • Aznar M.C.
        • Bergler-Klein J.
        • et al.
        2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European Society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology Society (IC-OS) -.
        Eur Heart J. 2022 Aug 26; ehac244
        • Lehmann L.H.
        • Cautela J.
        • Palaskas N.
        • Baik A.H.
        • Meijers W.C.
        • Allenbach Y.
        • et al.
        Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review.
        JAMA Cardiol. 2021; 6: 1329-1337
        • Bonaca M.P.
        • Olenchock B.A.
        • Salem J.E.
        • Wiviott S.D.
        • Ederhy S.
        • Cohen A.
        • et al.
        Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology.
        Circulation. 2019; 140: 80-91
        • Herrmann J.
        • Lenihan D.
        • Armenian S.
        • Barac A.
        • Blaes A.
        • Cardinale D.
        • et al.
        Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
        Eur Heart J. 2022; 43: 280-299
        • Nowatzke J.
        • Guedeney P.
        • Palaskas N.
        • Lehmann L.
        • Ederhy S.
        • Zhu H.
        • et al.
        Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry.
        Eur J Cancer. 2022; S0959–8049: 443-449
      1. Palassin P, Faillie JL, Coustal C, Quantin X, Topart D, Roubille F, et al. Under-reporting of major cardiac adverse events with immune checkpoint inhibitors in clinical trials: importance of post-marketing pharmacovigilance surveys. J Clin Oncol. Accepted for publication Sept 2022.

        • Ferreira V.M.
        • Schulz-Menger J.
        • Holmvang G.
        • Kramer C.M.
        • Carbone I.
        • Sechtem U.
        • et al.
        Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.
        J Am Coll Cardiol. 18 déc 2018; 72: 3158-3176
        • Collet J.P.
        • Thiele H.
        • Barbato E.
        • Barthélémy O.
        • Bauersachs J.
        • Bhatt D.L.
        • et al.
        2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
        Eur Heart J. 2021 Apr 7; 42: 1289-1367
        • Nguyễn T.
        • Maria A.T.J.
        • Ladhari C.
        • Palassin P.
        • Quantin X.
        • Lesage C.
        • et al.
        Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.
        Ann Rheum Dis. 2022; 81: e32

      Linked Article